Company profile: Frontier Medicines
1.1 - Company Overview
Company description
- Provider of a biopharmaceutical drug discovery platform integrating chemoproteomics, covalent chemistry, and machine learning to accelerate medicine development; programs include a dual KRASG12C inhibitor (FMC-376) targeting active and inactive forms in cancers and AutoTAC for autophagy-driven targeted degradation; tools span ML/AI prioritization, chemoproteomics to identify druggable hotspots, and a covalent fragment library.
Products and services
- AutoTAC™: A novel targeted degradation approach utilizing the autophagy degradation system to expand drug development targets
- Dual KRASG12C Inhibitor (FMC-376): A novel dual inhibitor that targets both active and inactive forms of the KRASG12C mutation in cancers
- The Frontier™ Platform: A proprietary drug discovery platform combining chemoproteomics, covalent chemistry, and machine learning to identify small molecule–protein hotspots, prioritize targets, and architect screening strategies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Frontier Medicines
Emerald Cloud Lab
HQ: United States
Website
- Description: Provider of technology platforms for biotechnology innovation, including ECL Command Center for remote experiment design and execution; ECL Constellation for organizing data into a knowledge graph; access to 200+ automated lab instruments (HPLC, Mass Spectrometry, NMR); and 4,500+ data visualization, analysis, and simulation functions via point-and-click or direct command entry.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Emerald Cloud Lab company profile →
Bio Balance
HQ: United States
Website
- Description: Provider of studies of biomedical problems.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bio Balance company profile →
Clarivate
HQ: United States
Website
- Description: Provider of trusted insights, analytics, data, workflow solutions, and deep domain expertise that help innovators discover, protect, and commercialize ideas faster. Offers real-world healthcare data, formulary tools, patient identification and assistance, and consulting in commercial strategy, evidence/value/access, and technology, including systems integration, data informatics, and custom solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Clarivate company profile →
Consensus
HQ: United States
Website
- Description: Provider of an AI-powered search engine that finds answers in scientific research, enabling discovery and consumption of the world's expert knowledge.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Consensus company profile →
Title21
HQ: United States
Website
- Description: Provider of fully integrated, flexible software for health science organizations to increase operational efficiency, close compliance gaps, and improve patient care. Products include cellular therapy and BMT data management platforms; quality management (document control, CAPA, audit, training); audit management; equipment management for preventive maintenance and calibration; and web-based CAPA software.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Title21 company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Frontier Medicines
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Frontier Medicines
2.2 - Growth funds investing in similar companies to Frontier Medicines
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Frontier Medicines
4.2 - Public trading comparable groups for Frontier Medicines
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →